Enhertu significantly improved both progression-free and overall survival in DESTINY ...

Retrieved on: 2022-02-21 07:30:04

Tags for this article:

Clinical medicine

Cancer

Health

Breast cancer

Immunology

Antibody-drug conjugates

Trastuzumab

HER2/neu

Breast cancer management

Triple-negative breast cancer

Trastuzumab emtansine

Antibody-drug conjugate

Daiichi Sankyo

Daiichi Sankyo Company Limited

AstraZeneca

Click the tags to see associated articles and topics

Enhertu significantly improved both progression-free and overall survival in DESTINY .... View article details on HISWAI: https://pipelinereview.com/index.php/2022022180393/Antibodies/Enhertu-significantly-improved-both-progression-free-and-overall-survival-in-DESTINY-Breast04-trial-in-patients-with-HER2-low-metastatic-breast-cancer.html

Excerpt

First HER2-low metastatic breast cancer Phase III results for AstraZeneca and Daiichi Sankyo's Enhertu offer potential to redefine how the disease ...

Article found on: pipelinereview.com

View Original Article